Primary prevention

Awareness of human papillomavirus (HPV) infection and transmission may help prevent its spread through behavior modification. Abstinence prevents transmission of HPV.[3][28] Barrier methods of contraception such as condoms also may decrease the risk of HPV transmission, but they are not entirely effective.[28] CDC: condom fact sheet in brief Opens in new window

There are 3 HPV vaccines available: bivalent (types 16 and 18); quadrivalent (types 6, 11, 16, and 18); and 9-valent (types 6, 11, 16, 18, 31, 33, 45, 52, and 58). The quadrivalent and 9-valent vaccines are approved to prevent genital warts. In the US, only the 9-valent vaccine is available, and is approved for use in females and males aged 9 to 45 years of age.

The US schedule for HPV immunization: CDC: recommended immunization schedule for children and adolescents ages 18 years or younger Opens in new window CDC: recommended adult immunization schedule for ages 19 years or older Opens in new window​​

All children and adults ≤26 years should receive a 2- or 3-dose series of HPV vaccine depending on age at initial vaccination or condition.[29][30]​​​ Routine HPV vaccination is recommended for adolescents at age 11 or 12 years, although it can be given from age 9 years.​​[29][31]​​​​ Healthy adolescents ages 9 to 14 years should receive 2 doses of HPV vaccine; the second dose should be administered 6 to 12 months after the first dose.[31]​ For those initiating vaccination on or after their 15th birthday, 3 doses of HPV vaccine are recommended (0, 1-2, 6 month schedule).[31]​​ Immunocompromised people should receive a 3-dose series, even if vaccination is initiated at ages 9-14 years.[29][30]​​​

Shared clinical decision-making regarding HPV catch-up vaccination is recommended in people ages 27 to 45 years who were not adequately vaccinated when younger.[30][32]​ HPV vaccination is not recommended in pregnant women.[30]​​

If a patient has previously had an abnormal Pap test or history of genital warts, HPV vaccination is still recommended.​[33]

Male circumcision may protect against HPV infection, and therefore related disease, in both men and women.[34] Further research is required.

Impact of HPV vaccination

Within 6 years of HPV vaccination availability, HPV 6/11/16/18 infections among Australian women (ages 18-24) and sexually active US females (ages 14-24) decreased by 86% after 3 doses, and 76% after ≥1 dose, respectively, compared with contemporaneous unvaccinated women.[35] Decreased HPV infection prevalence among unvaccinated females in the vaccine era compared with the prevaccine era suggested herd protection.[35]

In 2011, genital wart prevalence had decreased by up to 92.6% among HPV vaccine-eligible Australian females ages <21 years (from 11.5% in 2007 to 0.85% in 2011).[36][37] None of the females ages <21 years who had been vaccinated were diagnosed with genital warts.[36][37]

Secondary prevention

All women with genital warts, as with all sexually active females, should undergo annual cervical cytological screening.[74] After 3 negative annual screenings, women may be screened at less frequent intervals as directed by their healthcare provider.​[6]​

Screening for other STIs, such as chlamydia, gonorrhea, syphilis, hepatitis B, and HIV infection, should be performed in patients with genital warts.[75][76]

Use of this content is subject to our disclaimer